Tin tức & Cập nhật

Add-on duloxetine exerts null effect on chronic osteoarthritis pain
Add-on duloxetine exerts null effect on chronic osteoarthritis pain
12 Jan 2022
COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
11 Jan 2022

Vaccines against SARS-CoV-2 has a safety profile that is similar in patients with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) and those with noninflammatory RMD (NI-RMD), according to a study. The vaccines are well tolerated with rare reports of I-RMD flare and serious adverse events.

COVID-19 vaccines safe for patients with rheumatic, musculoskeletal disease
11 Jan 2022
Shorter flare duration best indicator of treatment success in gout
Shorter flare duration best indicator of treatment success in gout
14 Dec 2021

Patients with gout consider flare duration, flare frequency, and pain severity when thinking about treatment efficacy over time, according to a study. Of these factors, shorter flare duration is deemed to be the most common indicator of successful treatment.

Shorter flare duration best indicator of treatment success in gout
14 Dec 2021
Opioid medication linked to patients’ familiarity, perceptions of efficacy
Opioid medication linked to patients’ familiarity, perceptions of efficacy
13 Dec 2021

Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

Opioid medication linked to patients’ familiarity, perceptions of efficacy
13 Dec 2021
Psoriatic arthritis weakens hand strength
Psoriatic arthritis weakens hand strength
12 Dec 2021

Patients with psoriatic arthritis exhibit reduced hand grip strength, with the deterioration of skill, coordination, and functionality of hand commensurate with the severity of psoriatic arthritis, a study has found.

Psoriatic arthritis weakens hand strength
12 Dec 2021
Guselkumab safe, well tolerated in patients with psoriatic arthritis
Guselkumab safe, well tolerated in patients with psoriatic arthritis
10 Dec 2021
Ixekizumab effective for difficult-to-treat psoriatic arthritis
Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021 bởiAudrey Abella

The monoclonal antibody ixekizumab improved the signs and symptoms of psoriatic arthritis (PsA) in PsA patients with inadequate response to one or two tumour necrosis factor inhibitors (TNFis), suggests results from a post hoc subanalysis of the SPIRIT-P2 trial.

Ixekizumab effective for difficult-to-treat psoriatic arthritis
08 Dec 2021